Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

BACKGROUND: Current data suggest that platinum-based combination therapy is the standard first-line treatment for biliary tract cancer. EGFR inhibition has proven beneficial across a number of gastrointestinal malignancies; and has shown specific advantages among KRAS wild-type genetic subtypes of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hezel, A F, Noel, M S, Allen, J N, Abrams, T A, Yurgelun, M, Faris, J E, Goyal, L, Clark, J W, Blaszkowsky, L S, Murphy, J E, Zheng, H, Khorana, A A, Connolly, G C, Hyrien, O, Baran, A, Herr, M, Ng, K, Sheehan, S, Harris, D J, Regan, E, Borger, D R, Iafrate, A J, Fuchs, C, Ryan, D P, Zhu, A X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119993/
https://www.ncbi.nlm.nih.gov/pubmed/24960403
http://dx.doi.org/10.1038/bjc.2014.343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119993/
https://www.ncbi.nlm.nih.gov/pubmed/24960403
http://dx.doi.org/10.1038/bjc.2014.343

Ejemplares similares